The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
NFκB: a promising target for natural products in cancer chemoprevention
Abstract
The transcription factor nuclear factor kappa B (NFκB) is found in nearly all animal cell types. It is involved in cellular responses to stimuli such as stress, cytokines, free radicals, ultraviolet irradiation, oxidized LDL and microbial antigens, and has been shown to regulate the expression of a number of genes including bcl‐2, bcl‐xl, cIAP, suvivin, TRAF, COX‐2, MMP‐9, iNOS and cell cycle‐regulatory components. Many carcinogens, inflammatory agents and tumor promoters have been shown to activate NFκB, and resulting tumors demonstrate misregulated NFκB. Incorrect regulation of NFκB has been linked to inflammatory and autoimmune diseases, septic shock, viral infection and improper immune development. Aberrant regulation of NFκB is involved in cancer development and progression as well as in drug resistance. Inhibitors of NFκB mediate effects potentially leading to antitumor responses or greater sensitivity to the action of antitumor agents. Tools have been developed for the rapid assessment of NFκB activity, so in concert with a better understanding of NFκB activation mechanisms, many agents capable of suppressing NFκB activation have been identified. The present article focuses on the functions of NFκB, its role in human cancer and the therapeutic potential and benefit of targeting NFκB by natural products in cancer chemoprevention. Copyright © 2010 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hayden, M. S., & Ghosh, S. (2004) · Genes & Development · doi:10.1101/gad.1228704 · Cited by 3,842
Missing Pieces in the NF-κB Puzzle
Ghosh, S., & Karin, M. (2002) · Cell · doi:10.1016/s0092-8674(02)00703-1 · Cited by 3,638 · cited 3×
“The IKK protein contains two subunits which can be purifi ed as a 700–900 kDa complex (IKK1 and IKK2), and a regulatory subunit, NEMO (NFκB essential modifi er) (Rothwarf and Karin, 1999; Ghosh and Karin, 2002).”
BackgroundNuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519 · cited 1×
“Blocking NFκB can cause tumor cells to cease proliferation or become more sensitive to the action of antitumor agents (Karin, 2006).”
BackgroundThe two NF-κB activation pathways and their role in innate and adaptive immunity
Bonizzi, G., & Karin, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.03.008 · Cited by 2,535
Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A., & Karin, M. (1995) · Science · doi:10.1126/science.270.5234.286 · Cited by 2,390
Integrating cell-signalling pathways with NF-κB and IKK function
Perkins, N. D. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2083 · Cited by 2,350
Orlowski, R. Z., Stinchcombe, T. E., Mitchell, B. S., Shea, T. C., Baldwin, A. S., Stahl, S., Adams, J., Esseltine, D.-L., Elliott, P. J., Pien, C. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.133 · Cited by 760
Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B
Wahl, C., Liptay, S., Adler, G., & Schmid, R. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci992 · Cited by 742
Kasibhatla, S., Brunner, T., Genestier, L., Echeverri, F., Mahboubi, A., & Green, D. R. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80054-4 · Cited by 721
Cited by
Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance
Shapira, A., Livney, Y. D., Broxterman, H. J., & Assaraf, Y. G. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.003 · Cited by 504
Cancer Prevention With Natural Compounds
Gullett, N. P., Ruhul Amin, A. R. M., Bayraktar, S., Pezzuto, J. M., Shin, D. M., Khuri, F. R., Aggarwal, B. B., Surh, Y.-J., & Kucuk, O. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.06.014 · Cited by 485
Self-citationSynergy research: Approaching a new generation of phytopharmaceuticals
Wagner, H. (2011) · Fitoterapia · doi:10.1016/j.fitote.2010.11.016 · Cited by 372
Signaling pathways and therapeutic interventions in gastric cancer
Lei, Z.-N., Teng, Q.-X., Tian, Q., Chen, W., Xie, Y., Wu, K., Zeng, Q., Zeng, L., Pan, Y., Chen, Z.-S., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01190-w · Cited by 322
Proteasome inhibitors in cancer therapy
Crawford, L. J., Walker, B., & Irvine, A. E. (2011) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-011-0121-7 · Cited by 299
Metadata
- Authors
- Luqman, S., & Pezzuto, J. M.
- Venue
- Phytotherapy Research
- Publisher
- Wiley
- Published
- 2010-06-24
- Volume
- 24
- Issue
- 7
- Pages
- 949-963
- ISSN
- 0951-418X (ISSN-L)
- 1099-1573
- OpenAlex
- W1982504977
- Cited by
- 184
- References
- 9
- FWCI
- 7.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.